Keyphrases
Patients with Heart Failure
71%
Atrial Fibrillation
68%
Heart Failure with Preserved Ejection Fraction (HFpEF)
65%
Heart Failure
39%
Pathophysiological Pathways
19%
Preserved Ejection Fraction
19%
Left Ventricular Ejection Fraction
17%
Sex Differences
16%
Beta-blockers
15%
Chronic Heart Failure
12%
Up-titration
12%
Sinus Rhythm
11%
Recommended Dose
11%
Optimal Dose
10%
Biomarker Profile
10%
Heart Failure Medication
10%
Angiotensin Receptor Blockers
10%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
10%
Reduced Ejection Fraction
10%
Asia
9%
Ethnic Differences
9%
EuroQol 5-dimension Questionnaire
9%
Genetic Risk
9%
Kansas City Cardiomyopathy Questionnaire
9%
Prospective Observational Study
9%
Atrial Function
9%
Quality of Life
9%
Paroxysmal Atrial Fibrillation
9%
Molecular Pathways
9%
With Woman
9%
Angiotensin-converting Enzyme Inhibitor (ACEi)
9%
New-onset Heart Failure
9%
Growth Differentiation factor-15 (GDF-15)
9%
Candesartan
9%
Charm
9%
Treatment Discontinuation
9%
Failure Data
9%
Heart Failure Hospitalization
7%
BIOSTAT-CHF
6%
Dose Level
6%
Over-representation Analysis
5%
Renin-angiotensin System Inhibitors
5%
High Dose
5%
Target Dose
5%
Medicine and Dentistry
Heart Failure
100%
Atrial Fibrillation
58%
Heart Failure with Reduced Ejection Fraction
48%
Ejection Fraction
27%
Biological Marker
27%
Sex Difference
26%
Sinus Rhythm
19%
Optimal Drug Dose
15%
Beta Adrenergic Receptor Blocking Agent
14%
Heart Left Ventricle Ejection Fraction
13%
ACE Inhibitor
13%
Angiotensin Receptor Antagonist
13%
Pathophysiology
12%
Heart Failure with Preserved Ejection Fraction
12%
Drug Therapy
11%
Titrimetry
11%
Recommended Drug Dose
10%
Paroxysmal Atrial Fibrillation
9%
Growth Differentiation Factor 15
9%
Angiotensin Converting Enzyme 2
9%
Aldosterone
9%
Angiotensin
9%
Renin
9%
Cohort Study
9%
Heart Atrium Function
9%
Heart Rhythm
6%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
70%
Heart Failure with Reduced Ejection Fraction
44%
Atrial Fibrillation
39%
Biological Marker
20%
Beta Adrenergic Receptor Blocking Agent
14%
Angiotensin Receptor Antagonist
14%
Dipeptidyl Carboxypeptidase Inhibitor
13%
Growth Differentiation Factor 15
9%
Angiotensin Converting Enzyme 2
9%
Cardiomyopathy
9%
Angiotensin
9%
Renin
9%
Aldosterone
9%
Cohort Study
9%
Candesartan
9%
Congestive Heart Failure
9%
